NCT02331706View on ClinicalTrials.gov

IFN-DLI for Relapsed Acute Leukemia After Allo-SCT

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

November 11, 2016

Study Completion Date

November 11, 2017

Conditions
Leukemia
Interventions
DRUG

Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT02331706 - IFN-DLI for Relapsed Acute Leukemia After Allo-SCT | Biotech Hunter | Biotech Hunter